Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: A phase 2/3 randomized, controlled study of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen.
Authors
Marilyn Fontaine
Brighton, MA;
Marilyn Fontaine , Sarah Pilgrim , Thomas Schuetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05506943
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS640)
DOI
10.1200/JCO.2023.41.4_suppl.TPS640
Abstract #
TPS640
Poster Bd #
P9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
First Author: Olivia Aranha
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A single-arm, open-label, phase Ⅱ study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.
First Author: Xiaofeng Chen
Poster
2023 ASCO Annual Meeting
Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.
First Author: YunJung Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer